This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rose, W. E.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rose, W. E.
Right arrow Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2009, p. 805-807, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.01009-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model {triangledown}

Warren E. Rose,1,3,5 Steven N. Leonard,1,3 Kerri L. Rossi,1 Glenn W. Kaatz,2,4 and Michael J. Rybak1,2,3*

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences,1 School of Medicine, Wayne State University, Detroit, Michigan 48201,2 Detroit Receiving Hospital, Detroit, Michigan 48201,3 John D. Dingell Department of Veteran's Affairs Medical Center, Detroit, Michigan 48201,4 University of Wisconsin School of Pharmacy, Madison, Wisconsin 537055

Received 28 July 2008/ Returned for modification 4 September 2008/ Accepted 11 November 2008


arrow
ABSTRACT
 
The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (108 CFU/ml). A high bacterial load of >105 CFU/ml persisted for all strains with doses up to 5 g every 12 h against high inoculum amounts. No change in the vancomycin MIC was detected in any isolate at a moderate inoculum amount (106 CFU/ml), and bactericidal activity occurred only against the non-hVISA isolate (time to 99% kill, 7.5 h; P = 0.001).


arrow
INTRODUCTION
 
The treatment of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections with vancomycin presents many therapeutic challenges. Patients with hVISA bacteremia have significantly higher rates of morbidity and high-bacterial-load infections than patients with non-hVISA multidrug-resistant S. aureus (MRSA). In addition, patients with hVISA bacteremia have been documented to have low initial vancomycin concentrations (<10 mg/liter) (1). The rate of vancomycin failure in serious infections associated with high bacterial loads is supported by the reduced vancomycin activity against high inoculum amounts in experimental in vitro and in vivo pharmacodynamic (PD) models (6, 7). Although low vancomycin concentrations have been associated with hVISA, the optimal treatment regimen with vancomycin remains undetermined. A vancomycin area under the concentration-time curve (AUC)/MIC ratio of ≥400 (free drug concentration [f] AUC/MIC of ≥180) has been associated with improved clinical and microbiological responses against standard MRSA (3, 9). The purpose of this study was to identify bacterial kill and reduction of susceptibility for high and moderate inoculum amounts of hVISA and non-hVISA isolates, utilizing a range of vancomycin regimens in an in vitro PD model.

(A portion of this work was presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 17-20 September 2007 [9a].)

Three S. aureus strains were employed: (i) Mu3, the first isolate with hVISA characteristics to be described, from Japan (4); (ii) MRSA 1629, a clinical hVISA isolate; and (iii) MRSA 3286, a clinical non-hVISA strain. Vancomycin was purchased from Sigma. Mueller-Hinton broth (Difco, Detroit, MI) supplemented with 25 mg/liter calcium and 12.5 mg/liter magnesium was used for all susceptibility and in vitro PD model assessments. MICs and minimum bactericidal concentrations were determined by broth microdilution or E-test according to Clinical and Laboratory Standards Institute methods (2). The MIC of vancomycin with the high inoculum amount was determined as previously described (6). The detection of hVISA was determined by population analysis-AUC profile and macrodilution E-test methodology (10).

A previously described in vitro pharmacokinetic (PK) and PD (PK/PD) model was utilized for all simulations, with amounts of 106 (moderate) and 108 (high) CFU/ml of inoculum (6). Vancomycin was evaluated by using a range for the fAUC/MIC over 0 to 24 h of 105 to 799 (750 to 5,000 mg every 12 h). The development of resistance was evaluated every 24 h by microtiter and E-test with a 0.5 McFarland standard of (i) samples directly from the model and (ii) subsequent bacterial growth on vancomycin-screening plates containing three and six times the organism's MIC. Vancomycin PKs were determined by using a fluorescence polarization immunoassay (Abbott Diagnostics TDx) and PK Analyst software (version 1.10; MicroMath Scientific Software) as previously described (6). Changes in CFU/ml at 24, 48, and 72 h were compared by two-way analysis of variance with Tukey's post hoc test. A P value of ≤0.05 was considered significant. (SPSS version 14; SPSS, Inc.).

Susceptibility results for all isolates at the moderate inoculum amount are listed in Table 1. The MICs for the high inoculum amount of MRSA 3286, hVISA 1629, and Mu3 were 4, 4, and 8, respectively. The PK values of the simulated dosing regimens shown in Table 1 were comparable to predicted values.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Pharmacokinetic and pharmacodynamic parameters of vancomycin dosing regimensa

The activities of vancomycin against all three isolates at the different inoculum amounts for a range of dosing regimens over 72 h are displayed in Fig. 1. With the high inoculum amount of all isolates, bactericidal activity at 24 h occurred in the majority of dosing regimens regardless of the organism tested. However, the additional killing effect beyond 24 h of exposure was minimal even at doses as high as 5 g every 12 h (fAUC/MIC, 799). A high bacterial load of approximately 105 organisms remained by the end of the 72 h for all strains.


Figure 1
View larger version (23K):
[in this window]
[in a new window]

  		FIG. 1. In vitro PD model activities for a range of vancomycin dosing simulations with from 1,000 to 5,000 mg every 12 h against high and moderate inoculum amounts of hVISA isolates Mu3 (A) and 1629 (B) and non-hVISA isolate 3286 (C) over 72 h.

The impact of hVISA expression on vancomycin activity was more evident with the moderate inoculum amount. Rapid bactericidal activity was achieved in MRSA 3286 within 8 h using vancomycin doses of 1,000 to 2,000 mg every 12 h (fAUC/MIC, 552 to 1,084). The time to achieve bactericidal activity with this strain was significantly more rapid and sustained with the moderate inoculum amount than with the high inoculum amount (7.5 versus 27.8 h; P < 0.001). In addition, an increased time to 99.9% kill and regrowth of ≥1 log were demonstrated for both of the hVISA strains (P = 0.001). There were no MIC changes detected for any test strain with the moderate inoculum amount (Table 1).

With the high inoculum amount, doses ranging from 750 to 2,000 mg every 12 h resulted in decreased susceptibility of the hVISA isolates. Although no resistance was detected with doses from 2.25 to 5 g every 12 h (fAUC/MIC, 799) for the hVISA isolates, these regimens had minimal activity in overall bacterial-load reduction. Vancomycin exposure of the non-hVISA 3286 did not result in susceptibility changes beyond the baseline.

The hVISA isolate Mu3 was discovered to be genetically related to Mu50, the first VISA, which is from Japan, and therefore represents an intermediate step from vancomycin-susceptible S. aureus to VISA (4). In our in vitro model study with Mu3, we were able to reproduce VISA-like phenotypic characteristics with dosing regimens ranging from 750 to 2,250 mg every 12 h (fAUC/MIC, 105 to 317) against a simulated high-bacterial-load infection, resulting in up to a fourfold change in the MIC. No MIC changes were found with the non-hVISA clinical isolate. In addition, MIC increases in hVISA only occurred with the high-bacterial-load simulations. We attribute this to the 1,000-times-greater organism burden with the high-bacterial-load simulation, resulting in an increased probability of the expression of a heterogeneous population.

The vancomycin killing activities in our in vitro PK/PD model appeared to be significantly affected by the inoculum amount and consistent with the results of prior studies (3, 6, 7). The moderate inoculum amount of our non-hVISA strain resulted in more-rapid and -sustained bactericidal activity. The antimicrobial activity in the first 24 h differed between the hVISA isolates in high and low inoculum amounts, but similar organism burdens remained after 72 h of vancomycin therapy. This suggests that a similar bacterial population survived the effects of vancomycin exposure and that tolerance may play a role in regrowth. The clinical reports of hVISA infections would support this theory since these clinical failures have corresponded to high-bacterial-load infections along with complicated and persistent bacteremia (1, 5, 8).

Overall, we demonstrated that vancomycin at doses ranging from 750 to 2,250 mg every 12 h (fAUC/MIC, 105 to 317) had poor activity against clinical strains of hVISA in an in vitro PK/PD model and resulted in a large organism burden with reduced vancomycin susceptibility after exposure to a high-bacterial-load simulation. The presence of hVISA and a high bacterial load both affect vancomycin activity, and patients with either of these circumstances may be at increased risk of treatment failure.


arrow
ACKNOWLEDGMENTS
 
There was no external funding of any kind supporting this work.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Anti-Infective Research Laboratory, Pharmacy Practice 4148, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201. Phone: (313) 993-4673. Fax: (313) 577-8915. E-mail: m.rybak{at}wayne.edu Back

{triangledown} Published ahead of print on 17 November 2008. Back


arrow
REFERENCES
 
    1
  1. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.[CrossRef][Medline]
    2. 2
  2. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. M100-S16. Clinical Laboratory Standards Institute, Wayne, PA.
    3. 3
  3. Craig, W. A., and D. R. Andes. 2006. In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VISA (hVISA) and VSSA in the neutropenic murine thigh-infection model, abstr. A-644. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 27-30 September 2006.
    4. 4
  4. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.[CrossRef][Medline]
    5. 5
  5. Howden, B. P., P. B. Ward, P. G. Charles, T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.[CrossRef][Medline]
    6. 6
  6. LaPlante, K. L., and M. J. Rybak. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672.[Abstract/Free Full Text]
    7. 7
  7. Lee, D., Y. Murakami, T. Stamstad, K. Marchillo, A. J., D. R. Andes, and W. A. Craig. 2007. Inoculum effect of daptomycin, linezolid, vancomycin, and ceftobiprole with Staphylococcus aureus and Streptococcus pneumoniae in neutropenic mice at 105 and 107 CFU in opposite thighs, abstr. A-37. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17-20 September 2007.
    8. 8
  8. Maor, Y., G. Rahav, N. Belausov, D. Ben-David, G. Smollan, and N. Keller. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45:1511-1514.[Abstract/Free Full Text]
    9. 9
  9. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942.[CrossRef][Medline]
    10. 9
  10. Rose, W. E., K. L. Lau, G. W. Kaatz, and M. J. Rybak. 2007. Relationships between vancomycin (V) pharmacodynamics and the emergence of V intermediate Staphylococcus aureus (VISA) from heteroresistant VISA (hVISA) in an in vitro pharmacokinetic/pharmacodynamic model (IVPM), abstr. A-13. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17-20 September 2007.
    11. 10
  11. Wootton, M., A. P. MacGowan, T. R. Walsh, and R. A. Howe. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, February 2009, p. 805-807, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.01009-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sader, H. S., Jones, R. N., Rossi, K. L., Rybak, M. J. (2009). Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother 64: 1024-1028 [Abstract] [Full Text]  
  • Zhanel, G. G., Voth, D., Nichol, K., Karlowsky, J. A., Noreddin, A. M., Hoban, D. J. (2009). Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 64: 364-369 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rose, W. E.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rose, W. E.
Right arrow Articles by Rybak, M. J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»